CULVER CITY, Calif. – May 12, 2026 – Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, today announced the University of Michigan Health Weiser Center for Prostate Cancer has adopted its Unfold AI platform, marking the first adoption of the technology in the Midwest. The move brings world class AI-driven 3D prostate cancer mapping into one of the nation’s top urologic oncology programs, supporting more informed and individualized treatment decisions for patients.
One in eight men are projected to face a prostate cancer diagnosis in their lifetime, with growing rates of advanced disease rising in Michigan in the last decade. At the same time, clinicians continue to rely on imaging methods that existing imaging and biopsy can miss or underestimate clinically significant disease, creating ongoing challenges in determining the right course of treatment.
Unfold AI is an FDA-cleared, multimodal AI platform that combines patient-specific data to create a personalized 3D cancer map, revealing the true size and extent of disease and uncovering hidden cancer. By delivering a more complete and accurate view of the tumor and disease spread, Unfold AI empowers physicians to make more informed, patient-specific treatment decisions and reduces the risk of over- or under-treatment.
Ad Statistics
Times Displayed: 5266
Times Visited: 18 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
“Up to 20% of clinically significant prostate cancer is invisible on standard prostate MRI, and Prostate MRI can significantly underestimate the size of the cancer” said Andrew M. Wood, M.D., urological surgeon at U-M Health, leading the use of Unfold AI at the institution. “Having access to Unfold AI adds a valuable tool to our evaluation and treatment of this disease, allowing for additional precision in tumor ablation procedures and a more personalized treatment paradigm tailored to each patient.”
In peer-reviewed studies, Unfold AI has demonstrated improvements in physician identification of tumor extent, increasing sensitivity from 37% to 97%, and helps physicians predict the cancer’s spread into nearby anatomy with 92% accuracy, compared to 52% using MRI alone.
“Partnering with University of Michigan Health represents an important step in bringing Unfold AI to leading cancer centers across the country,” said Shyam Natarajan, PhD, co-founder and CEO of Avenda Health. “Expanding our footprint into the Midwest is a critical step in our mission to democratize access to precision prostate cancer care, empowering physicians to personalize treatment decisions and improve outcomes for patients.”
